Editas Medicine, Inc.
EDITHealthcareNASDAQBiotechnology · Last scanned May 30, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Editas Medicine, Inc. focuses on Biotechnology services and products. Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company carries a $531.0M market cap, placing it firmly in the small-cap category. The company develops a proprietary gene editing platform based on CRISPR technology.
Market Cap
$531.0M
Beta
2.14
P/E (TTM)
—
P/E (Fwd)
-3.69
EPS (TTM)
$-1.14
EPS (Fwd)
$-0.94
ROE
-326.1%
ROA
-27.0%
Cash
$123.6M
Total Debt
$17.3M
Free CF
-$73.8M
52W Change
95.5%
Annual Financials
Cash vs Debt
Editas Medicine, Inc. holds $123.6M in cash against $17.3M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$73.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -326.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $19.7M (2022) to $40.5M (2025), reflecting a 106% increase over the period.
With a beta above 1.5, EDIT tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing EDIT.